On Thursday, an expert panel of the central drug regulatory authority recommended market authorization for Serum Institute of India′s Covid vaccine Covovax as a heterologous booster dose for adults who have completed their primary vaccination schedule, including two doses of Covishield or Covaxin.

Recently, Dr. Prakash Kumar Singh, director, Serum Institute of India (SII), wrote a letter to the Drugs Controller General of India (DCGI) seeking approval for Covovax as a heterologous booster dose.

An official source revealed that on Wednesday, the subject expert committee (SEC) of the CDSCO discussed the issue and recommended the market authorization of the Covid vaccine Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin.